Google to Allow Cannabis and CBD Ads in Some US Regions

Dec.27.2022
Google to Allow Cannabis and CBD Ads in Some US Regions
Google to allow some cannabis and CBD ads in select US regions starting next month.

Starting next month, Google will no longer prohibit the advertising of certain cannabis and CBD products in certain regions of the United States.


Last week, this internet giant announced that it will update its policies on "risky products and services, as well as healthcare and pharmaceuticals", to allow for marijuana advertisements in California, Colorado, and Puerto Rico.


Google announced that starting on January 20, 2023, FDA-approved medications containing cannabidiol as well as topical marijuana-based CBD products containing THC levels of 0.3% or less can be advertised within these jurisdictions.


Some formats, including YouTube bumper ads, will no longer meet the criteria for placement," the company said. "CBD will be removed from the list of unapproved drugs and supplements. Advertising for other CBD-based products, including supplements, food additives, and inhalers, will continue to be prohibited.


It is currently unclear why Google has restricted policy changes to these two states and one US territory, as marijuana and its derivatives, such as CBD, are legal at the federal level and these products are sold nationwide.


Furthermore, a drug called Epidiolex, primarily made from cannabis, has been approved by the federal government for the treatment of severe epilepsy seizures. This has raised questions about further regional restrictions.


Google is partnering with a company called LegitScript to verify the eligibility of cannabis-related products for advertising and allow for "instant" submission of applications.


In the United States, only externally applied CBD products that have been certified by LegitScript are allowed to be promoted on Google, according to the company. The certification process requires products seeking promotion to (1) provide samples for testing to ensure they comply with legal THC restrictions and (2) supply LegitScript with third-party analytical certificates.


Scott Roth, CEO of LegitScript, stated in a press release, "When people see the LegitScript seal on your product or website, they know that your operation is safe and transparent.


In an industry that still commonly faces issues with contaminated, substandard, or illegal products, it is more important than ever to give consumers confidence that the CBD products they purchase have undergone proper scrutiny," he said.


Advertisers certified by LegitScript and FDA-approved CBD drugs "must first be certified by Google before they can start advertising," according to a Google notification summarized by Search Engine Land. "From the date of publication of the form on January 20, 2023, advertisers may apply for certification from Google.


Google's shift could be beneficial to the marijuana industry, especially if it ultimately expands to cover all states and regions. For advocates, the policy change is also a symbolic victory and consistent with the evolving stance of other actors in the tech field on this issue.


In 2019, Google received criticism for announcing that its app store, Google Play, would prohibit marijuana products. However, it appears that the company has now relaxed this stance, as delivery services like Eaze can now be found on its app marketplace.


Apple has expedited the standardization of marijuana applications, having lifted a similar ban in 2021.


Meanwhile, Google co-founder Sergey Brin joked at a post-election meeting in 2016 about providing joints for employees.


In recent news regarding technology and marijuana, Twitter appears to have ended a federal partnership this month that provided users who searched certain drug-related keywords (including "marijuana") with recommendations for drug treatment. No such recommendations appeared for searches related to "alcohol.


In 2019, a Facebook executive discussed how the social media giant could use visual artificial intelligence to detect "policy-violating content," including advertisements promoting the sale of marijuana on the platform.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives